LIFR and breast carcinoma: In our studies, pharmacologic LIFR inhibition revealed an unexpected trend whereby breast cancer cells treated with the inhibitor had significantly elevated phosphorylated p38 and a p38/ERK signaling ratio compared to vehicle treated cells, regardless of PTHrP mutant expression.